Reducing Emissions from Antibiotics Production– demands, tools and experiences
Emissions of antibiotics from production sites contribute significantly to the promotion of AMR, with consequences not only limited to health issues, but also impacting ecosystems and people’s livelihoods. Currently there is a lack of incentives, regulation as well as tools and experiences to foster changing practices. The usual approach for reducing pollution of industry effluents is focused at energy and resource costly end of the pipe solutions. To promote a sustainable approach to the issue SIWI’s project REAP-effect is engaging with antibiotics manufacturers to look into the resource flows of the production processes. Identifying the potential for resource savings and more efficient points for removing pollutants will enable the companies to reduce both pollution and become less vulnerable to resource scarcity. Supported by the UNDP led Initiative on Sustainable Procurement in the Health Sector (SPHS), both procurement and supplier perspectives are accounted for in the project.
The purpose of the showcase is to discuss potential methodologies for improved supply chain management for antibiotics production, based on first experiences from project REAP-effect. Initial results from industry dialogue will be the starting point for engaging procurers and regulators for necessary next steps.
Project presentation :
Reducing Emissions from Antibiotics Production
Lizzie Sagrelius / Iris Panorel, SIWI
11:10 Reflections from stakeholders and project partners
Rosemary Kumwenda, SPHS
Frans Vlaar, DSM-Sinochem
Damiano de Felice, Access to Medicine Foundation
11:30 Panel discussion and audience engagement
Nicolai Schaaf, SIWI
11:45 End of session
The showcase was opened by Iris Panorel and Lizzie Örn Sagrelius from Swedish Water House. They gave a brief overview of the project REAP-effect. They discussed the logic behind the project strategy and the issue of AMR as such and why manufacturing of pharmaceuticals is an important part of the life cycle to adress to minimize AMR.
Since the project is still in an initial phase the focus was not so much on results as was anticipated but focused more on the need for dialogue among the different stakeholders, why the invited speakers from SPHS/UNDP, Access to Medicine Foundation and DSM-Sincohem were given more space.
Rosemary Kumwenda from SPHS/UNDP, who is the partner organization in the project, gave an overview of how SPHS works and presented their two projects SHiPP and REAP-effect.
Frans Vlaar from DSM-Sinochem, the first pharmaceutical company that has agreed to join the REAP-effect project, talked about the importance of addressing the issue of AMR and highlighted the responsibility of the industry.
Damiano de Felice from Access to Medicine Foundation presented their work and discussed the importance of incentive structures and co-operation.
The session was concluded by Nicolai Schaaf from Swedish Water House.
Unfortunately there was not much time left for audience engagement only a few of the questions raised were discussed.
The recommendation that could be derived from the showcase is that in spite of a growing momentum for the issue there is still a great need for further discussions and a need for a joint platform and commitments from the key-stakeholders. The development of tools and methodologies for a more sustainable production of pharmaceuticals in general and antibiotics in particular is urgent.